Patient recruitment company for diabetes trials, Medicollect, increases investments and enters UK market.

Copenhagen, Denmark – Medicollect today announced its expansion into UK, increasing its acceptance footprint across the continent. The addition of the British network extends the company’s reach to 3, 4 million diabetes patients.

According to a report produced for the drug company Novartis clinical trials in the United Kingdom cost significantly more than in other European countries, in large because of poor rates of recruitment (source).

“This means that there is an increasing need for innovative and reliable solutions that address market needs,” says Torben Lind, COO at Medicollect. “Our investment in UK will secure that test patients for clinical diabetes trials in United Kingdom will be provided at the same fast, safe and reliable way that Medicollect has serviced the Scandinavian market.

Through collaborating with diabetes stakeholders in UK and Denmark, Medicollect is directly contributing to bringing medical innovation to patients faster and support United Kingdom’s transformation to once more being a strong center for clinical trials.

Want to know more?
Contact Torben Lind

blog-example

Patient recruitment company, Medicollect, in close cooperation with Danish Diabetes Association

Medicollect has taken the initiative to establish the Danish group for diabetics who want to participate in clinical research, The Diabetics Panel.

Danish Diabetes Association will invite their members to sign up for the free membership of The Diabetics Panel, and by doing so, they acknowledges their members’ wish to know about the current diabetes research.

Medicollect also acknowledge the importance of the work done by Danish Diabetes Association, and will therefore send out information to all panel members about Danish Diabetes Association.

Medicollect is proud of this cooperation, and Torben Lind, COO, states: “Cooperation at such strategic level is a testimony to the seriousness, and professionalism with which we work, and we are proud to be acknowledged by a institution as fundamental for Danish diabetics as Danish Diabetics Association”.

So far, the cooperation spans until summer 2015, with the possibility of being prolonged into a more ongoing framework.

Want to know more?
Contact Torben Lind

blog-msd

Patient recruitment company, Medicollect, continues final vendor qualification streak with MSD

Earlier this year, Medicollect achieved its first vendor milestone, when worlds second largest pharmaceutical company, Novartis, finalized the detailed vendor qualification process.

Now, MSD has also approved all SOP’s submitted by Medicollect for vendor qualification, making it the second finalized procedure from a global pharmaceutical company in mere months.

Pharmaceutical companies and CROs have shown huge interest in Medicollect’s services. It is a clear testimony to Medicollect’s innovative aspects and professionalism that global pharmaceutical companies are eager to enter into vendor partnerships with Medicollect.

As Torben Lind, COO in Medicollect, phrases it: “Medicollect focuses exclusively on solving the recruitment challenge faced by companies involved with clinical trial, and our services come across as the best solution the market has to offer right now”.

Want to know more?
Contact Torben Lind